MARC details
| 000 -LEADER |
|---|
| fixed length control field |
15148nam a2200373 a 4500 |
| 001 - ACCESSION NUMBER |
|---|
| control field |
016527214 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
CUTN |
| 005 - DATE AND TIME OF LATEST TRANSACTION |
|---|
| control field |
20210422111841.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
050505s2006 ne a b 001 0 eng d |
| 010 ## - LIBRARY OF CONGRESS CONTROL NUMBER |
|---|
| LC control number |
2005928309 |
| 015 ## - NATIONAL BIBLIOGRAPHY NUMBER |
|---|
| National bibliography number |
GBA548303 |
| Source |
bnb |
| 016 7# - NATIONAL BIBLIOGRAPHIC AGENCY CONTROL NUMBER |
|---|
| Record control number |
101267040 |
| Source |
DNLM |
| 016 7# - NATIONAL BIBLIOGRAPHIC AGENCY CONTROL NUMBER |
|---|
| Record control number |
013215263 |
| Source |
Uk |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| International Standard Book Number |
0127597603 (alk. paper) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| International Standard Book Number |
9780127597607 (alk. paper) |
| 035 ## - SYSTEM CONTROL NUMBER |
|---|
| System control number |
(OCoLC)ocm65616865 |
| Canceled/invalid control number |
(OCoLC)65616865 |
| -- |
(OCoLC)60607543 |
| -- |
(OCoLC)64571772 |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
NLM |
| Transcribing agency |
NLM |
| Modifying agency |
CGU |
| -- |
BAKER |
| -- |
UKM |
| -- |
CUS |
| -- |
VAM |
| -- |
YDXCP |
| -- |
LVB |
| -- |
CGC |
| -- |
VRC |
| -- |
BTCTA |
| 042 ## - AUTHENTICATION CODE |
|---|
| Authentication code |
pcc |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER |
|---|
| Classification number |
RM171.7 |
| Item number |
.B56 2006 |
| 060 00 - NATIONAL LIBRARY OF MEDICINE CALL NUMBER |
|---|
| Classification number |
2006 B-532 |
| 060 10 - NATIONAL LIBRARY OF MEDICINE CALL NUMBER |
|---|
| Classification number |
WH 450 |
| Item number |
B65515 2006 |
| 060 #4 - NATIONAL LIBRARY OF MEDICINE CALL NUMBER |
|---|
| Classification number |
WH 450 |
| Item number |
BLO |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER |
|---|
| Classification number |
615.39 |
| Edition number |
22 |
| 245 00 - TITLE STATEMENT |
|---|
| Title |
Blood substitutes / |
| Statement of responsibility, etc |
edited by Robert M. Winslow. |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT) |
|---|
| Place of publication, distribution, etc |
Amsterdam ; |
| -- |
London : |
| Name of publisher, distributor, etc |
Elsevier Academic Press, |
| Date of publication, distribution, etc |
c2006. |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
xx, 548 p. : |
| Other physical details |
ill. ; |
| Dimensions |
28 cm. |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE |
|---|
| Bibliography, etc |
Includes bibliographical references and index. |
| 505 ## - FORMATTED CONTENTS NOTE |
|---|
| Formatted contents note |
List of Contributors<br/>Preface<br/>Acknowledgements<br/>Abbreviations<br/>Introduction<br/>Section 1: Background<br/>Introduction<br/>Chapter 1: Historical Background<br/>INTRODUCTION<br/>BLOOD CIRCULATION AND TRANSFUSION<br/>WORLD WAR II<br/>FIRST ‘BLOOD SUBSTITUTES’<br/>BLOOD PLASMA, SERUM AND ALBUMIN<br/>CELL-FREE HEMOGLOBIN<br/>CURRENT STATUS<br/>SUMMARY<br/>Chapter 2: Transfusion Medicine<br/>HISTORY OF BLOOD TRANSFUSION<br/>ORGANIZATION OF BLOOD SERVICES<br/>AVAILABILITY OF BLOOD<br/>RED BLOOD CELL COMPONENTS<br/>RED CELL COMPATIBILITY<br/>UNIVERSAL RED CELLS<br/>RED CELL MODIFICATION<br/>ADVERSE EVENTS ASSOCIATED WITH RED CELL TRANSFUSION<br/>IMMUNOMODULATORY EFFECTS<br/>THE COST OF RED CELLS<br/>THE ROLE OF RED CELL SUBSTITUTES<br/>Chapter 3: Regulatory Perspectives on Clinical Trials for Oxygen Therapeutics in Trauma and Transfusion Practice<br/>GENERAL REGULATORY BACKGROUND IN THE UNITED STATES<br/>CONSIDERATIONS FOR CLINICAL TRIALS IN TRAUMA<br/>CONSIDERATIONS IN TRANSFUSION AVOIDANCE<br/>SUMMARY<br/>Section 2: Physiological Basis<br/>Introduction<br/>Chapter 4: Clinical Physiology: Oxygen Transport and the Transfusion Trigger<br/>INTRODUCTION<br/>OXYGEN REQUIREMENTS<br/>LOCAL REGULATION OF OXYGEN SUPPLY: THE MICROCIRCULATION<br/>OXYGEN UPTAKE IN THE LUNG<br/>THE ‘OPTIMAL’ HEMATOCRIT<br/>OXYGEN DELIVERY, OXYGEN UPTAKE AND THE ‘CRITICAL OXYGEN’<br/>BLOOD TRANSFUSION AND OXYGEN SUPPLY<br/>THE ‘TRANSFUSION TRIGGER’<br/>Chapter5: The Role of Oxygen and Hemoglobin Diffusion in Oxygen Transport by Cell-free Hemoglobins<br/>INTRODUCTION<br/>OXYGEN DIFFUSION AND ITS BARRIERS IN THE CIRCULATION<br/>FACILITATED DIFFUSION OF OXYGEN BY OXYHEMOGLOBIN<br/>RATE LIMITING STEPS OF IN VIVO GAS EXCHANGE<br/>FACILITATED OXYGEN TRANSPORT AND VASOCONSTRICTION<br/>FACILITATED DIFFUSION AND HYPEROXYGENATION OF ARTERIOLES<br/>SUMMARY<br/>Chapter 6: Oxygen Transport Properties of Hemoglobin-Based Oxygen Carriers: Studies using Artificial Capillaries and Mathematical Simulation<br/>INTRODUCTION<br/>IN VITRO SIMULATION OF OXYGEN TRANSPORT<br/>CURRENT STATE OF OXYGEN CARRIER STUDIES IN ARTIFICIAL CAPILLARIES<br/>CURRENT STATE OF MATHEMATICAL SIMULATION STUDIES<br/>EXAMPLES OF EXPERIMENTS AND SIMULATIONS<br/>IMPLICATIONS FOR IN VIVO OXYGEN TRANSPORT<br/>SUMMARY<br/>Chapter 7: Mechanisms of Oxygen Transport in the Microcirculation: Effects of Cell-Free Oxygen Carriers<br/>INTRODUCTION<br/>THE DISTRIBUTION OF OXYGEN ON THE CIRCULATION<br/>OXYGEN DELIVERY AND CONSUMPTION<br/>ANEMIA AND HYPEROXIA<br/>THE HEMOGLOBIN – OXYGEN EQUILIBRIUM CURVE<br/>TISSUE RESPIRATION<br/>SUMMARY<br/>ACKNOWLEDGMENTS<br/>Chapter 8: Shear Stress Mechanotransduction and the Flow Properties of Blood<br/>INTRODUCTION<br/>SHEAR STRESS AND THE RELEASE OF VASOACTIVE MEDIATORS<br/>MECHANOTRANSDUCTION AND MECHANOSENSORS<br/>THE ROLE OF THE GLYCOCALYX<br/>CHANGES OF SHEAR STRESS IN THE MICROCIRCULATION<br/>EFFECTS IN THE PLASMA LAYER<br/>BLOOD SUBSTITUTES AND MECHANOTRANSDUCTION<br/>ACKNOWLEDGMENTS<br/>Chapter 9: Local Regulation of Blood Flow<br/>INTRODUCTION<br/>TISSUE OXYGEN SUPPLY AND DEMAND<br/>CELLULAR METABOLIC FEEDBACK<br/>OXYGEN-SENSITIVE MECHANISMS<br/>MECHANISMS OF FUNCTIONAL HYPEREMIA<br/>MECHANICAL STIMULI FOR FLOW REGULATION<br/>INTEGRATIVE ASPECTS OF FLOW REGULATION<br/>ACKNOWLEDGMENTS<br/>Section 3: Clinical Applications<br/>Introduction<br/>Chapter 10: Clinical Indications for Blood Substitutes and Optimal Properties<br/>INTRODUCTION<br/>TRAUMA/RESUSCITATION<br/>ELECTIVE SURGERY<br/>RED CELL INCOMPATIBILITY<br/>ISCHEMIC DISEASE AND ANGIOPLASTY<br/>EXTRACORPOREAL ORGAN PERFUSION<br/>CELL CULTURE MEDIA<br/>HEMATOPOIETIC STIMULATION<br/>CARDIOPLEGIA<br/>SICKLE-CELL ANEMIA<br/>TUMOR THERAPY<br/>CHRONIC ANEMIA<br/>RESEARCH<br/>REQUIREMENTS FOR A BLOOD SUBSTITUTE<br/>Chapter 11: Crystalloid Solutions<br/>INTRODUCTION<br/>PHYSIOLOGICAL PRINCIPLES<br/>DISTRIBUTION VOLUMES OF WATER, SODIUM AND PROTEIN<br/>KINETIC DISTRIBUTION VOLUMES OF FLUIDS<br/>CRYSTALLOID SOLUTIONS<br/>USE OF CRYSTALLOID FLUIDS IN SURGICAL PROCEDURES<br/>USE OF CRYSTALLOID FLUIDS FOR REPLACEMENT OF BLOOD LOSS<br/>OTHER EFFECTS OF CRYSTALLOID INFUSION<br/>SUMMARY<br/>Chapter 12: Hemoglobin-Based Oxygen Carriers as Resuscitative Solutions for Trauma and Combat Casualty Care<br/>INTRODUCTION<br/>REQUIREMENTS FOR COMBAT CASUALTY CARE<br/>RELEVANT PROPERTIES OF HBOCs FOR TRAUMA AND COMBAT CASUALTY CARE<br/>INTRAOPERATIVE TRIALS<br/>PRE-HOSPITAL RESUSCITATION<br/>PLASMA VOLUME EXPANSION<br/>CARDIAC OUTPUT<br/>OXYGEN UPTAKE VERSUS OXYGEN DELIVERY<br/>HYPOTENSIVE RESUSCITATION<br/>NEW FORMULATIONS<br/>SUMMARY<br/>Chapter 13: Surgical Hemorrhage<br/>INTRODUCTION<br/>POTENTIAL CLINICAL BENEFITS OF HBOCs IN SURGICAL CARE<br/>POTENTIAL ROLE OF HBOCs IN SURGICAL CARE<br/>EXCEPTION FROM INFORMED CONSENT FOR TRAUMA TRIALS<br/>CLINICAL EVALUATION OF TETRAMERIC HEMOGLOBIN IN TRAUMA<br/>CLINICAL SAFETY OF POLYHEME™ IN TRAUMA<br/>CLINICAL EFFICACY OF POLYHEME TRAUMA CARE<br/>THE NEXT GENERATION OF HBOCs FOR SURGICAL CARE<br/>ACKNOWLEDGMENTS<br/>Chapter 14: Clinical Trials in Cardiac Surgery<br/>INTRODUCTION<br/>HEMOGLOBIN SOLUTIONS<br/>PERFLUOROCARBON EMULSIONS<br/>SUMMARY<br/>Chapter 15: Hemodilution<br/>INTRODUCTION<br/>MECHANISMS OF ADAPTATION TO REDUCED HEMOGLOBIN<br/>MICROCIRCULATORY CHANGES AND TISSUE OXYGENATION<br/>TISSUE OXYGENATION<br/>BRAIN FUNCTION IN DILUTIONAL ANEMIA<br/>PLASMA VISCOSITY<br/>EXTREME HEMODILUTION<br/>HYPEROXIC HEMODILUTION<br/>SUMMARY<br/>Chapter 16: Clinical Hemodilution<br/>INTRODUCTION<br/>INDICATIONS FOR ACUTE NORMOVOLEMIC HEMODILUTION<br/>PHYSIOLOGICAL COMPENSATORY MECHANISMS<br/>HEMODILUTION PROCEDURES<br/>EFFICACY OF HEMODILUTION<br/>ADJUNCTS TO ANH<br/>SUMMARY<br/>Chapter 17: Potential for Blood Substitutes in Tissue Ischemia<br/>INTRODUCTION<br/>PERIPHERAL ARTERIAL OCCLUSIVE DISEASE<br/>TREATMENT AVAILABLE FOR CHRONIC CRITICAL LEG ISCHEMIA<br/>POTENTIAL FOR BLOOD SUBSTITUTES IN THE TREATMENT OF CCLI<br/>SUMMARY<br/>Section 4: Toxicity and Side Effects<br/>Introduction<br/>Chapter 18: Redox and Radical Reactions of Hemoglobin Solutions: Toxicities and Protective Strategies<br/>INTRODUCTION<br/>OXIDATIVE MECHANISMS<br/>HEMOGLOBIN AND CELL-SIGNALING PATHWAYS<br/>ANTIOXIDATIVE PROTECTIVE STRATEGIES<br/>SUMMARY<br/>Chapter 19: Pro-Oxidant Activity of Hemoglobin and Endothelial Cytotoxicity<br/>INTRODUCTION<br/>PRO-OXIDANT ACTIVITY OF HEMOGLOBIN<br/>HEMOGLOBIN-MEDIATED ENDOTHELIAL CYTOTOXICITY IN VITRO<br/>PRO-OXIDANT ACTIVITY OF HEMOGLOBIN AND VASCULAR TOXICITY IN VIVO<br/>SUMMARY<br/>Chapter 20: Renal Toxicity<br/>INTRODUCTION<br/>HISTORY AND BACKGROUND<br/>CURRENT STATE OF KNOWLEDGE<br/>HEMOGLOBIN TOXICITY TO RENAL VASCULATURE<br/>FUNCTIONAL CONSEQUENCES OF HEMOGLOBIN TOXICITY<br/>ACUTE RENAL FAILURE<br/>SUMMARY<br/>FUTURE DIRECTIONS<br/>Chapter 21: Hemoglobin and Neurotoxicity<br/>INTRODUCTION<br/>IN VITRO EXPERIMENTS<br/>IN VIVO EXPERIMENTS<br/>TISSUE RESPONSE TO HEMOGLOBIN METABOLITES AND POSSIBLE NEUROPROTECTION<br/>CLINICAL EXPERIENCE WITH HBOCs<br/>Chapter 22: The Role of Inflammation in the Toxicity of Hemoglobin-Based Oxygen Carriers<br/>INTRODUCTION<br/>THE INFLAMMATORY RESPONSE<br/>BLOOD VESSELS<br/>BLOOD SUBSTITUTES AND INFLAMMATION<br/>MICROVESSELS AND INTESTINAL MUCOSA<br/>CLINICAL IMPLICATIONS OF INFLAMMATION DURING USE OF BLOOD SUBSTITUTES<br/>ANTICIPATED FUTURE DIRECTIONS<br/>SUMMARY<br/>Chapter 23: Hemoglobin-Induced Myocardial Lesions<br/>INTRODUCTION<br/>BACKGROUND<br/>ANIMAL MODELS<br/>LESION CHARACTERISTICS<br/>MECHANISM OF HEMOGLOBIN-INDUCED MYOCARDIAL LESIONS<br/>CO-MEDICAMENTS<br/>SUMMARY<br/>ACKNOWLEDGEMENTS<br/>Section 5: Perfluorocarbon-Based Oxygen Carriers<br/>Introduction<br/>Chapter 24: Fluorocarbon Emulsions as in vivo Oxygen Delivery Systems: Background and Chemistry<br/>FLUOROCARBON CHEMISTRY<br/>OXYGEN DISSOLVING AND DELIVERING CAPACITY: GAS-LIKE LIQUIDS<br/>PERFLUOROCARBON EMULSIONS FOR IN VIVO OXYGEN TRANSPORT<br/>DEVELOPMENT OF INJECTABLE FLUOROCARBON EMULSIONS<br/>THE SEARCH FOR IMPROVED EMULSIONS<br/>Chapter 25: Fluosol®: The First Commercial Injectable Perfluorocarbon Oxygen Carrier<br/>INTRODUCTION<br/>ORIGINS OF FLUOSOL<br/>CHEMISTRY, COMPOSITION AND PRODUCTION<br/>PRECLINICAL STUDIES<br/>CLINICAL TRIALS<br/>Studies in North America<br/>FAILURE OF REGULATORY APPROVAL OF FLUOSOL FOR THE TREATMENT OF ANEMIA<br/>PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY<br/>OTHER APPLICATIONS FOR FLUOSOL<br/>LESSONS LEARNED FROM FLUOSOL<br/>OTHER ‘FIRST-GENERATION’ EMULSIONS<br/>Chapter 26: Perftoran®<br/>INTRODUCTION<br/>HISTORY AND COMPOSITION OF PERFTORAN<br/>PRECLINICAL STUDIES<br/>CLINICAL TRIALS WITH PERFTORAN<br/>CURRENT USAGE OF PERFTORAN<br/>CLINICAL IMPLICATIONS<br/>THE FUTURE OF PERFTORAN<br/>SUMMARY<br/>ACKNOWLEDGMENTS<br/>Chapter 27: Rational Development of Oxyfluor™<br/>INTRODUCTION<br/>EVOLUTION OF PERFLUOROCARBONS FOR OXYGEN TRANSPORT<br/>DEVELOPMENT OF OXYFLUOR™<br/>OXYFLUOR REGULATORY STATUS<br/>THE FUTURE OF OXYFLUOR AND HEMAGEN<br/>Chapter 28: Oxygent™, a Perfluorochemical-Based Oxygen Therapeutic for Surgical Patients<br/>INTRODUCTION<br/>EMULSION CHARACTERISTICS<br/>NON-CLINICAL SAFETY<br/>CLINICAL SAFETY<br/>PRECLINICAL EFFICACY<br/>POTENTIAL CLINICAL APPLICATIONS<br/>PHASE II CLINICAL STUDIES<br/>PHASE III CLINICAL STUDIES<br/>FUTURE CLINICAL DEVELOPMENT<br/>ACKNOWLEDGMENTS<br/>Section 6: Hemoglobin-Based Oxygen Carriers<br/>Introduction<br/>Chapter 29: The Structural and Functional Properties of Hemoglobin and their Relevance for a Hemoglobin-Based Blood Substitute<br/>INTRODUCTION<br/>THE STRUCTURE OF HEMOGLOBIN<br/>DERIVATIVES WITH HEME LIGANDS<br/>SUBUNIT INTERFACES AND TETRAMER–DIMER DISSOCIATION<br/>COOPERATIVE OXYGEN BINDING<br/>STEREOCHEMICAL CONSEQUENCES OF LIGAND BINDING<br/>CONTROL OF OXYGEN AFFINITY<br/>NON-HEME LIGANDS: H+, Cl−, CO2 AND 2,3-DPG<br/>NITRIC OXIDE<br/>AUTOXIDATION<br/>ACKNOWLEDGMENTS<br/>Chapter 30: Hemoglobin Modification<br/>INTRODUCTION<br/>REACTIVITY OF HEMOGLOBIN<br/>AMINO-TERMINAL MODIFICATION<br/>MODIFICATION AT THE 2,3-DPG BINDING SITE<br/>αα-CROSSLINK (LYSINE G6(99) α1–LYSINE G6(99)α2)<br/>SURFACE, MULTISITE POLYMERIZING REAGENTS<br/>CONJUGATED HEMOGLOBIN<br/>RECOMBINANT HEMOGLOBIN<br/>HEMOGLOBIN SOURCES<br/>Chapter 31: Designing Recombinant Hemoglobin for Use as a Blood Substitute<br/>INTRODUCTION<br/>GENETICALLY CROSSLINKED HEMOGLOBIN<br/>OXYGEN DELIVERY<br/>THE HYPERTENSIVE SIDE EFFECT<br/>NO DIOXYGENATION BY OXYHEMOGLOBIN<br/>EXPRESSION OF rHB IN E. COLI<br/>SUMMARY<br/>ACKNOWLEDGMENTS<br/>Chapter 32: Design, Conformational, Functional and Physiological Characterization of Recombinant Polymeric Heme-Proteins<br/>INTRODUCTION<br/>DESIGN OF RECOMBINANT HEME PROTEIN POLYMERS<br/>BIOCHEMICAL PROPERTIES<br/>PHYSIOLOGICAL PROPERTIES<br/>ENDOTHELIAL PERMEABILITY (EXTRAVASATION)<br/>SUMMARY<br/>ACKNOWLEDGMENTS<br/>Chapter 33: αα-Crosslinked Hemoglobin<br/>THE NEED FOR A BLOOD SUBSTITUTE<br/>PRODUCTION<br/>CHARACTERIZATION<br/>PHARMACOKINETICS<br/>VASOCONSTRICTION<br/>HEMODYNAMICS<br/>MICROCIRCULATION<br/>ENDOTHELIUM<br/>OXYGEN TRANSPORT<br/>OXIDATION<br/>CENTRAL NERVOUS SYSTEM<br/>Chapter 34: DCLHb and rHb1.1<br/>‘TETRAMERIC’ MODIFIED HEMOGLOBINS<br/>DCLHb<br/>RECOMBINANT HEMOGLOBINS<br/>RETROSPECTIVE<br/>Chapter 35: Clinical Studies with DCLHb<br/>INTRODUCTION<br/>PRECLINICAL CARDIAC LESIONS<br/>PHASE I STUDY<br/>PHASE II STUDIES<br/>PHASE III STUDIES<br/>EUROPEAN PRODUCT APPLICATION FOR CARDIAC SURGERY<br/>TRAUMA STUDIES: THE BEGINNING OF THE END<br/>THE END OF DCLHb<br/>LESSONS LEARNED<br/>Chapter 36: Hemopure® (HBOC-201, Hemoglobin Glutamer-250 (Bovine)): Preclinical Studies<br/>INTRODUCTION<br/>PRODUCT CHARACTERISTICS<br/>PHARMACOLOGICAL ACTION<br/>PRECLINICAL STUDIES OF TISSUE OXYGENATION AND TRAUMA<br/>CARDIOVASCULAR STUDIES<br/>HEMODILUTION AND COMPLETE BLOOD REPLACEMENT<br/>CARDIAC FUNCTION, OUTPUT AND METABOLISM<br/>POTENTIAL INDICATIONS FOR HBOC-201<br/>SUMMARY<br/>Chapter 37: HBOC-201 (Hemoglobin Glutamer-250 (Bovine), Hemopure®): Clinical Studies<br/>INTRODUCTION<br/>PHASE I STUDIES IN HUMAN VOLUNTEERS<br/>PHASE I/II STUDIES<br/>PHASE II STUDIES<br/>PHASE III STUDY<br/>OTHER POPULATIONS AND CASE STUDIES<br/>SUMMARY<br/>Chapter 38: Polyhemoglobin–Enzymes as New-Generation Blood Substitutes and Oxygen Therapeutics<br/>INTRODUCTION<br/>POLYHEMOGLOBIN–CATALASE–SUPEROXIDE DISMUTASE<br/>POLYHEMOGLOBIN–TYROSINASE<br/>SUMMARY<br/>Chapter 39: Surface Decoration of Hemoglobin with Polyethylene Glycol<br/>PROTEIN MODIFICATION WITH PEG<br/>HEMOGLOBIN MODIFICATION WITH PEG<br/>VASOACTIVITY OF PEG-MODIFIED HEMOGLOBIN<br/>NEW PARADIGMS FOR THE DESIGN OF HEMOGLOBIN-BASED BLOOD SUBSTITUTES<br/>NEW PEG CHEMISTRY STRATEGIES<br/>Structural and functional properties of Hb-PEG5K6<br/>MODIFICATION NEEDED TO NEUTRALIZE VASOACTIVITY<br/>MOLECULAR SHIELDING BY PEG MODIFICATION<br/>SUMMARY<br/>ACKNOWLEDGMENTS<br/>Chapter 40: Hemospan® (MP4), A Human Hemoglobin Modified with Maleimide-Polyethylene Glycol<br/>INTRODUCTION<br/>THE AUTOREGULATORY HYPOTHESIS<br/>CHEMISTRY AND PHYSICAL PROPERTIES<br/>NON-CLINICAL STUDIES<br/>TOXICOLOGY/SAFETY<br/>CLINICAL LABORATORY INTERFERENCE<br/>CLINICAL INDICATIONS<br/>CLINICAL TRIALS<br/>SUMMARY<br/>Chapter 41: Dextran–Hemoglobin<br/>INTRODUCTION<br/>HIGH YIELD OF DxHB<br/>PROTECTION OF KIDNEYS<br/>NON-ENTRY INTO LYMPH<br/>OXYGEN AFFINITY<br/>PHYSICAL STABILITY<br/>IN VIVO STUDIES<br/>POTENTIAL FOR DxHb<br/>Chapter 42: Development of Non-Extravasating Hemoglobin-Based Oxygen Carriers<br/>INTRODUCTION<br/>FUMARYL-CROSSLINKED BOVINE HEMOGLOBIN<br/>SEBACYL-CROSSLINKED TETRAMERIC HEMOGLOBIN (DECA)<br/>ADIPYL-CROSSLINKED BOVINE HEMOGLOBIN<br/>ZERO-LINK POLYMERIC HEMOGLOBIN<br/>OXYGEN DELIVERY BY HIGH AND LOW AFFINITY CARRIERS<br/>SUMMARY<br/>ACKNOWLEDGMENTS<br/>Section 7: Liposomes and Related Products<br/>Introduction<br/>Chapter 43: Liposome-Encapsulated Hemoglobin: History, Preparation and Evaluation<br/>HISTORICAL PERSPECTIVE<br/>PREPARATION OF LIPOSOME-ENCAPSULATED HEMOGLOBIN<br/>PROPERTIES<br/>ENDOTOXIN INTERACTION<br/>CIRCULATION TIME<br/>TOXICITY<br/>OXYGEN DELIVERY<br/>STORAGE STABILITY<br/>SUMMARY<br/>ACKNOWLEDGMENTS<br/>Chapter 44: Hemoglobin Vesicles as a Molecular Assembly: Characteristics of Preparation Process and Performances as Artificial Oxygen Carriers<br/>IMPORTANCE OF CELLULAR STRUCTURE<br/>PREPARATION OF HEMOGLOBIN VESICLES<br/>REGULATION OF OXYGEN AFFINITY<br/>STORAGE STABILITY<br/>ENDOTOXIN<br/>HEMOGLOBIN VESICLES AS OXYGEN CARRIERS IN VIVO<br/>SUMMARY<br/>ACKNOWLEDGMENTS<br/>Chapter 45: Nanodimension Biodegradable Polymeric Membrane Artificial Red Blood Cells<br/>INTRODUCTION<br/>PROPERTIES OF HEMOGLOBIN POLYLACTIDE NANOCAPSULES<br/>PEG-PLA COPOLYMER Hb NANOCAPSULES<br/>Effect of crosslinking the newly formed Hb nanocapsules<br/>ENZYMES AND MULTIENZYMES<br/>PREVENTION OF METHEMOGLOBIN FORMATION<br/>IMPLICATIONS FOR BLOOD SUBSTITUTE DEVELOPMENT<br/>ACKNOWLEDGMENTS<br/>Chapter 46: Albumin-Heme: A Synthetic Heme-Based Oxygen Carrier<br/>INTRODUCTION<br/>RATIONALE FOR ALBUMIN-HEME<br/>OXYGEN BINDING AND PHYSICOCHEMICAL CHARACTERISTICS<br/>BLOOD COMPATIBILITY IN VITRO<br/>IN VIVO EFFECTS<br/>PRECLINICAL SAFETY<br/>FUTURE RESEARCH<br/>ACKNOWLEDGMENTS<br/>Index<br/>Plate |
| 650 12 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
Blood Substitutes. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
Blood substitutes. |
| 700 1# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Winslow, Robert M., |
| Dates associated with a name |
1941-2009 |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Source of classification or shelving scheme |
Dewey Decimal Classification |
| Koha item type |
General Books |
